Opendata, web and dolomites

AMYPAD SIGNED

Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "AMYPAD" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://amypad.eu/
 Total cost 27˙329˙288 €
 EC max contribution 11˙999˙886 € (44%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-05-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 4˙699˙355.00
2    FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER ES (BARCELONA) participant 1˙417˙125.00
3    IXICO TECHNOLOGIES LIMITED UK (LONDON) participant 1˙196˙136.00
4    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 981˙375.00
5    CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE FR (TOULOUSE CEDEX 3) participant 803˙145.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 753˙375.00
7    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 697˙125.00
8    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 557˙750.00
9    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 519˙000.00
10    ALZHEIMER EUROPE LU (LUXEMBOURG) participant 200˙500.00
11    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 175˙000.00
12    GE HEALTHCARE LIMITED UK (LITTLE CHALFONT) participant 0.00
13    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
14    LIFE MOLECULAR IMAGING LTD UK (WARWICK) participant 0.00
15    UNIVERSITE DE GENEVE CH (GENEVE) participant 0.00

Map

 Project objective

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive, reason why this procedure is typically not reimbursed.

Understanding the value of imaging of β-amyloid using positron emission tomography (PET) provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of patients suspected of AD and their management; 2) stratify risk for AD and select homogenous groups for intervention; and 3) quantify treatment effects more accurately.

AMYPAD will address the above objectives by studying the onset, dynamics, and clinical relevance of brain β-amyloid in the spectrum from normal aging to preclinical and prodromal AD. We will use β-amyloid-PET in an unprecedented large number of subjects (n=4000) from population studies, as well as memory clinics cohorts, with repeat imaging in up to 2000. In close collaboration with EPAD (www.ep-ad.org), the cohorts will be followed with to determine (surrogate) outcomes of cognitive decline and neurodegeneration.

Lead from VU-VUmc, the Consortium brings together a word-class team of highly synergistic partners from across Europe constituting a highly experienced and efficient β-amyloid imaging network including the most active European PET sites, to ensure effective tracer delivery, access to patients and expertise to technical knowledge and disease modelling.

AMYPAD will establish the true value of β-amyloid PET across the severity range of AD. Patients and clinicians will benefit from better and cost-effective diagnostic procedures and management, while academics and industry will benefit from better disease understanding, clear reimbursement strategy and more rationale and efficient clinical trial design.

 Publications

year authors and title journal last update
List of publications.
2019 Fiona Heeman, Maqsood Yaqub, Isadora Lopes Alves, Kerstin Heurling, Johannes Berkhof, Juan Domingo Gispert, Santiago Bullich, Christopher Foley, Adriaan A. Lammertsma
Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
published pages: , ISSN: 2191-219X, DOI: 10.1186/s13550-019-0499-4
EJNMMI Research 9/1 2020-03-17
2020 Frank Jessen, Rebecca E Amariglio, Rachel F Buckley, Wiesje M van der Flier, Ying Han, José Luis Molinuevo, Laura Rabin, Dorene M Rentz, Octavio Rodriguez-Gomez, Andrew J Saykin, Sietske A M Sikkes, Colette M Smart, Steffen Wolfsgruber, Michael Wagner
The characterisation of subjective cognitive decline
published pages: 271-278, ISSN: 1474-4422, DOI: 10.1016/s1474-4422(19)30368-0
The Lancet Neurology 19/3 2020-03-17
2019 Enrico Fantoni, Lyduine Collij, Isadora Lopes Alves, Christopher Buckley, Gill Farrar
The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging
published pages: jnumed.119.23587, ISSN: 0161-5505, DOI: 10.2967/jnumed.119.235879
Journal of Nuclear Medicine 2020-03-17
2018 Mara ten Kate, Silvia Ingala, Adam J. Schwarz, Nick C. Fox, Gaël Chételat, Bart N. M. van Berckel, Michael Ewers, Christopher Foley, Juan Domingo Gispert, Derek Hill, Michael C. Irizarry, Adriaan A. Lammertsma, José Luis Molinuevo, Craig Ritchie, Philip Scheltens, Mark E. Schmidt, Pieter Jelle Visser, Adam Waldman, Joanna Wardlaw, Sven Haller, Frederik Barkhof
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
published pages: , ISSN: 1758-9193, DOI: 10.1186/s13195-018-0438-z
Alzheimer\'s Research & Therapy 10/1 2020-03-17
2017 Giovanni B Frisoni, Marina Boccardi, Frederik Barkhof, Kaj Blennow, Stefano Cappa, Konstantinos Chiotis, Jean-Francois Démonet, Valentina Garibotto, Panteleimon Giannakopoulos, Anton Gietl, Oskar Hansson, Karl Herholz, Clifford R Jack, Flavio Nobili, Agneta Nordberg, Heather M Snyder, Mara Ten Kate, Andrea Varrone, Emiliano Albanese, Stefanie Becker, Patrick Bossuyt, Maria C Carrillo, Chiara Cera
Strategic roadmap for an early diagnosis of Alzheimer\'s disease based on biomarkers
published pages: 661-676, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(17)30159-X
The Lancet Neurology 16/8 2020-03-17
2017 Matthias J. Ehrhardt, Pawel J. Markiewicz, Peter Richtárik, Jonathan Schott, Antonin Chambolle, Carola-Bibiane Schoenlieb
Faster PET reconstruction with a stochastic primal-dual hybrid gradient method
published pages: 58, ISSN: 1061-2464, DOI: 10.1117/12.2272946
Wavelets and Sparsity XVII Proceedings Volume 10394, Wavel 2020-03-17
2018 José Luis Molinuevo, Carolina Minguillon, Lorena Rami, Juan Domingo Gispert
The Rationale Behind the New Alzheimer’s Disease Conceptualization: Lessons Learned During the Last Decades
published pages: 1067-1077, ISSN: 1387-2877, DOI: 10.3233/JAD-170698
Journal of Alzheimer\'s Disease 62/3 2020-03-17
2019 Giovanni B Frisoni, Isadora Lopes Alves, Frederik Barkhof
IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer\'s disease
published pages: 519-520, ISSN: 1474-4422, DOI: 10.1016/s1474-4422(19)30166-8
The Lancet Neurology 18/6 2020-03-17
2019 Lyduine E. Collij, Elles Konijnenberg, Juhan Reimand, Mara ten Kate, Anouk den Braber, Isadora Lopes Alves, Marissa Zwan, Maqsood Yaqub, Daniëlle M.E. van Assema, Alle Meije Wink, Adriaan A. Lammertsma, Philip Scheltens, Pieter Jelle Visser, Frederik Barkhof, Bart N.M. van Berckel
Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18 F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
published pages: 541-547, ISSN: 0161-5505, DOI: 10.2967/jnumed.118.211532
Journal of Nuclear Medicine 60/4 2020-03-17
2019 Damiano Archetti, Silvia Ingala, Vikram Venkatraghavan, Viktor Wottschel, Alexandra L. Young, Maura Bellio, Esther E. Bron, Stefan Klein, Frederik Barkhof, Daniel C. Alexander, Neil P. Oxtoby, Giovanni B. Frisoni, Alberto Redolfi
Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer\'s disease
published pages: 101954, ISSN: 2213-1582, DOI: 10.1016/j.nicl.2019.101954
NeuroImage: Clinical 24 2020-03-17
2018 Pawel J. Markiewicz, Matthias J. Ehrhardt, Kjell Erlandsson, Philip J. Noonan, Anna Barnes, Jonathan M. Schott, David Atkinson, Simon R. Arridge, Brian F. Hutton, Sebastien Ourselin
NiftyPET: a High-throughput Software Platform for High Quantitative Accuracy and Precision PET Imaging and Analysis
published pages: 95-115, ISSN: 1539-2791, DOI: 10.1007/s12021-017-9352-y
Neuroinformatics 16/1 2020-03-17
2018 Giovanni B. Frisoni, Frederik Barkhof, Daniele Altomare, Johannes Berkhof, Marina Boccardi, Elisa Canzoneri, Lyduine Collij, Alexander Drzezga, Gill Farrar, Valentina Garibotto, Rossella Gismondi, Juan-Domingo Gispert, Frank Jessen, Miia Kivipelto, Isadora Lopes Alves, José-Luis Molinuevo, Agneta Nordberg, Pierre Payoux, Craig Ritchie, Irina Savicheva, Philip Scheltens, Mark E. Schmidt, Jonathan Schott, Andrew Stephens, Bart van Berckel, Bruno Vellas, Zuzana Walker, Nicola Raffa
AMYPAD Diagnostic and Patient Management Study: Rationale and design
published pages: , ISSN: 1552-5260, DOI: 10.1016/j.jalz.2018.09.003
Alzheimer\'s & Dementia 2020-03-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AMYPAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AMYPAD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More